Literature DB >> 23625092

The reliability of cardiogenic impedance and correlation with echocardiographic and plethysmographic parameters for predicting CRT time intervals post implantation.

Elena Sciaraffia1, Matthew R Ginks, John Gustafsson, Andreas Karlsson, C Aldo Rinaldi, Carina Blomström Lundqvist.   

Abstract

AIMS: Encouraging data have been reported on the use of cardiogenic impedance (CI) in cardiac resynchronization therapy (CRT) optimization. The purposes of this study were to: evaluate the stability of certain CI vectors 24 h postimplantation, study the correlation between these CI signals and selected echocardiographic parameters, and examine the possibility of non-invasive calibration of the patient-specific impedance-based prediction model. METHODS AND
RESULTS: Thirteen patients received a CRT-defibrillator device with monitor capability of the dynamic impedance between several electrodes. At implantation, a patient-specific impedance-based prediction model was created for identification of optimal atrioventricular and interventricular (VV) delays and calibrated on invasive measurements of left ventricular contractility (LV dP/dtmax). Simultaneously, non-invasive measurements of LV dP/dtmax and stroke volume (SV) were obtained using a finger plethysmograph. Patients were re-evaluated with echocardiography and new CI measurements the day after implantation. The hemodynamic benefit achieved by optimal VV setting according to the patient-specific impedance-based prediction model at follow-up was not as large as the one obtained at implantation. In a multivariate partial least square regression analysis, a correlation was found between aortic velocity time integral (VTI) and a generic linear combination of CI features (P < 0,005). No correlation was found between the patient-specific impedance-based prediction models and the non-invasive measurements of LV dP/dtmax and SV.
CONCLUSION: Cardiogenic impedance signals can be used to optimize CRT settings but seem less feasible as an ambulatory tool since calibration is required. The positive correlation between aortic VTI and CI measurements seems promising, although a larger cohort is required to create an echocardiography-based patient-specific model.

Entities:  

Mesh:

Year:  2013        PMID: 23625092     DOI: 10.1007/s10840-013-9795-5

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  21 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  Haemodynamic effects of changes in atrioventricular and interventricular delay in cardiac resynchronisation therapy show a consistent pattern: analysis of shape, magnitude and relative importance of atrioventricular and interventricular delay.

Authors:  Z I Whinnett; J E R Davies; K Willson; C H Manisty; A W Chow; R A Foale; D Wyn Davies; A D Hughes; J Mayet; D P Francis
Journal:  Heart       Date:  2006-05-18       Impact factor: 5.994

3.  Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The Resynchronization for the HemodYnamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study.

Authors:  Giuseppe Boriani; Cord Paul Müller; Karl Heinz Seidl; Rainer Grove; Jürgen Vogt; Wilfried Danschel; Andreas Schuchert; Pierre Djiane; Mauro Biffi; Thorsten Becker; Christophe Bailleul; Hans Joachim Trappe
Journal:  Am Heart J       Date:  2006-05       Impact factor: 4.749

4.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.

Authors:  S Cazeau; C Leclercq; T Lavergne; S Walker; C Varma; C Linde; S Garrigue; L Kappenberger; G A Haywood; M Santini; C Bailleul; J C Daubert
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

5.  Prospective comparison of echocardiographic atrioventricular delay optimization methods for cardiac resynchronization therapy.

Authors:  Jeffrey E Kerlan; Navinder S Sawhney; Alan D Waggoner; Mohit K Chawla; Sanjeev Garhwal; Judy L Osborn; Mitchell N Faddis
Journal:  Heart Rhythm       Date:  2006-02       Impact factor: 6.343

6.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

7.  Effect of optimizing the VV interval on left ventricular contractility in cardiac resynchronization therapy.

Authors:  Berry M van Gelder; Frank A Bracke; Albert Meijer; Lex J M Lakerveld; Nico H J Pijls
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

8.  Sequential biventricular pacing: evaluation of safety and efficacy.

Authors:  Peter T Mortensen; Peter Sogaard; Hassan Mansour; Jean Ponsonaille; Daniel Gras; Arnaud Lazarus; Wolfgang Reiser; Christine Alonso; Cecilia M Linde; Maurizio Lunati; Berthold Kramm; E Mark Harrison
Journal:  Pacing Clin Electrophysiol       Date:  2004-03       Impact factor: 1.976

9.  The optimized V-V interval determined by interventricular conduction times versus invasive measurement by LVdP/dtMAX.

Authors:  Berry M van Gelder; Albert Meijer; Frank A Bracke
Journal:  J Cardiovasc Electrophysiol       Date:  2008-04-09

10.  Relationship between intracardiac impedance and left ventricular contractility in patients undergoing cardiac resynchronization therapy.

Authors:  Matthew R Ginks; Elena Sciaraffia; Andreas Karlsson; John Gustafsson; Shoaib Hamid; Julian Bostock; Marcus Simon; Carina Blomström-Lundqvist; C Aldo Rinaldi
Journal:  Europace       Date:  2011-04-15       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.